FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551496057> ?p ?o ?g. }

• W2551496057 endingPage "184" @default.
• W2551496057 startingPage "175" @default.
• W2551496057 abstract "Purpose Immunologic surveillance of minimal residual disease in chronic myelogenous leukemia (CML) may be relevant for long-term control or cure of CML. Little is known about immune-modulatory effects of nilotinib in vivo, potentially predicting response to therapy. Patients and Methods A prospective and comprehensive flow cytometry–based immunomonitoring program paralleled the ENEST1st clinical study, investigating 52 nilotinib-naïve patients with chronic-phase CML. Data were verified in independent validation cohorts. Results T cells of patients with CML at diagnosis expressed low l-selectin (CD62L) levels, which was not a result of proportional aberrations of T-cell subsets. Low numbers of CD62L-expressing CD4 + and CD8 + T cells correlated with higher Sokal score, increased spleen size, and high leukocyte and peripheral-blood blast counts. At month 6 during nilotinib therapy, CD62L expression returned to levels of healthy individuals. The level of CD62L loss on T cells directly correlated with the extent of soluble CD62L (sCD62L) elevation. In parallel, the proteolytic activity of tumor necrosis factor α–converting enzyme (TACE; ADAM17, CD156b), the metalloproteinase shedding CD62L, was increased at diagnosis and significantly decreased during nilotinib treatment. High CD62L + expression on both CD4 + and CD8 + T cells and, vice versa, low sCD62L levels at CML diagnosis were linked to superior molecular responses. These findings were corroborated in independent validation cohorts. Conclusion We demonstrate the prognostic impact of CD62L shedding from T cells and increased sCD62L plasma levels at CML diagnosis on molecular response to tyrosine kinase inhibitor therapy in early chronic-phase CML. Functionally, decreased CD62L may be a consequence of increased TACE-mediated CD62L cleavage and potentially impairs immune-cell function. Larger prospective studies are ongoing to confirm the prognostic relevance of this finding." @default.
• W2551496057 created "2016-11-30" @default.
• W2551496057 creator A5000741825 @default.
• W2551496057 creator A5002600757 @default.
• W2551496057 creator A5006306448 @default.
• W2551496057 creator A5008868111 @default.
• W2551496057 creator A5018592613 @default.
• W2551496057 creator A5020528788 @default.
• W2551496057 creator A5026996624 @default.
• W2551496057 creator A5032138074 @default.
• W2551496057 creator A5032509163 @default.
• W2551496057 creator A5035964802 @default.
• W2551496057 creator A5038048953 @default.
• W2551496057 creator A5050873337 @default.
• W2551496057 creator A5054706986 @default.
• W2551496057 creator A5057088387 @default.
• W2551496057 creator A5061855057 @default.
• W2551496057 creator A5073313603 @default.
• W2551496057 creator A5083556952 @default.
• W2551496057 creator A5084751312 @default.
• W2551496057 date "2017-01-10" @default.
• W2551496057 modified "2023-09-25" @default.
• W2551496057 title "Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia" @default.
• W2551496057 cites W1963691526 @default.
• W2551496057 cites W1968685079 @default.
• W2551496057 cites W1968747503 @default.
• W2551496057 cites W1977092622 @default.
• W2551496057 cites W1977323533 @default.
• W2551496057 cites W1985281976 @default.
• W2551496057 cites W1988338839 @default.
• W2551496057 cites W1997842448 @default.
• W2551496057 cites W2028669471 @default.
• W2551496057 cites W2036009499 @default.
• W2551496057 cites W2036118441 @default.
• W2551496057 cites W2036842448 @default.
• W2551496057 cites W2037473428 @default.
• W2551496057 cites W2044312475 @default.
• W2551496057 cites W2051806138 @default.
• W2551496057 cites W2052923507 @default.
• W2551496057 cites W2058216377 @default.
• W2551496057 cites W2061887343 @default.
• W2551496057 cites W2063582323 @default.
• W2551496057 cites W2072834954 @default.
• W2551496057 cites W2073035156 @default.
• W2551496057 cites W2074881372 @default.
• W2551496057 cites W2088325902 @default.
• W2551496057 cites W2094371537 @default.
• W2551496057 cites W2099747692 @default.
• W2551496057 cites W2106266094 @default.
• W2551496057 cites W2106392592 @default.
• W2551496057 cites W2112505356 @default.
• W2551496057 cites W2114853101 @default.
• W2551496057 cites W2117356576 @default.
• W2551496057 cites W2117436137 @default.
• W2551496057 cites W2117806883 @default.
• W2551496057 cites W2119445810 @default.
• W2551496057 cites W2123050500 @default.
• W2551496057 cites W2132572195 @default.
• W2551496057 cites W2142699991 @default.
• W2551496057 cites W2149898816 @default.
• W2551496057 cites W2150873649 @default.
• W2551496057 cites W2155493075 @default.
• W2551496057 cites W2171694114 @default.
• W2551496057 cites W2202349529 @default.
• W2551496057 cites W2587781815 @default.
• W2551496057 doi "https://doi.org/10.1200/jco.2016.67.0893" @default.
• W2551496057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28056193" @default.
• W2551496057 hasPublicationYear "2017" @default.
• W2551496057 type Work @default.
• W2551496057 sameAs 2551496057 @default.
• W2551496057 citedByCount "28" @default.
• W2551496057 countsByYear W25514960572017 @default.
• W2551496057 countsByYear W25514960572018 @default.
• W2551496057 countsByYear W25514960572019 @default.
• W2551496057 countsByYear W25514960572020 @default.
• W2551496057 countsByYear W25514960572021 @default.
• W2551496057 countsByYear W25514960572022 @default.
• W2551496057 countsByYear W25514960572023 @default.
• W2551496057 crossrefType "journal-article" @default.
• W2551496057 hasAuthorship W2551496057A5000741825 @default.
• W2551496057 hasAuthorship W2551496057A5002600757 @default.
• W2551496057 hasAuthorship W2551496057A5006306448 @default.
• W2551496057 hasAuthorship W2551496057A5008868111 @default.
• W2551496057 hasAuthorship W2551496057A5018592613 @default.
• W2551496057 hasAuthorship W2551496057A5020528788 @default.
• W2551496057 hasAuthorship W2551496057A5026996624 @default.
• W2551496057 hasAuthorship W2551496057A5032138074 @default.
• W2551496057 hasAuthorship W2551496057A5032509163 @default.
• W2551496057 hasAuthorship W2551496057A5035964802 @default.
• W2551496057 hasAuthorship W2551496057A5038048953 @default.
• W2551496057 hasAuthorship W2551496057A5050873337 @default.
• W2551496057 hasAuthorship W2551496057A5054706986 @default.
• W2551496057 hasAuthorship W2551496057A5057088387 @default.
• W2551496057 hasAuthorship W2551496057A5061855057 @default.
• W2551496057 hasAuthorship W2551496057A5073313603 @default.
• W2551496057 hasAuthorship W2551496057A5083556952 @default.
• W2551496057 hasAuthorship W2551496057A5084751312 @default.
• W2551496057 hasConcept C121608353 @default.

• next